Katharina Kuenzel's Biography

Katharina Kuenzel, Researcher, FAU Erlangen-Nuremberg, Institute of Medical Biotechnology

Researcher at the Institute of Medical Biotechnology at Friedrich-Alexander-University Erlangen-Nuremberg, Germany.

Relevant Publications

Kuenzel, K., Friedrich, O., Gilbert, D.F. A recombinant human pluripotent stem cell line stably expressing halide-sensitive YFPI152L for GABAAR and GlyR-targeted high-throughput drug screening and toxicity testing. Front Mol Neurosci. 2016 Jun 28;9:51. doi: 10.3389/fnmol.2016.00051.

Abolpour Mofrad, S., Kuenzel., K., Friedrich, O., Gilbert, D.F. Optimizing neuronal differentiation of human pluripotent NT2 stem cells in monolayer cultures. Dev Growth Differ. 2016 Oct;58(8):664-676. doi: 10.1111/dgd.12323.

Gilbert, D.F., Stebbing, M.J., Kuenzel, K., Murphy, R.M., Zacharewicz, E., Buttgereit, A., Stokes, L., Adams, D.J., Friedrich, O. Store-operated Ca2+ entry (SOCE) and purinergic receptor-mediated Ca2+ homeostasis in murine BV2 microglia cells: Early cellular response to ATP-mediated microglia activation. Front Mol Neurosci. 2016 Oct 28;9:111. doi: 10.3389/fnmol.2016.00111.

GlyR and GABAAR Targeted High-throughput Screening and Toxicity Testing Using Human Pluripotent Stem Cells

Tuesday, 11 July 2017 at 14:30

Add to Calendar ▼2017-07-11 14:30:002017-07-11 15:30:00Europe/LondonGlyR and GABAAR Targeted High-throughput Screening and Toxicity Testing Using Human Pluripotent Stem CellsStem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Pluripotent stem cells like the human embryonal carcinoma cell line NT2 provide an enormous potential for drug discovery and toxicity testing. NT2 cells differentiate upon exposure to retinoic acid into cells with properties of neurons of the central nervous system and have been shown to express ion channels including glycine receptors (GlyRs) and gamma-aminobutyric acid receptors (GABAARs) which are both increasingly considered as attractive drug targets for therapeutic intervention. By stable transfection of NT2 cells with YFP-I152L, a halide-sensitive YFP (yellow fluorescent protein) variant, we created a cell line for studying the pharmacological properties of GlyRs and GABAARs in native neurons. In concentration-response experiments with the receptor agonist glycine and GABA as well as with receptor-specific drugs we demonstrated the applicability of the established NT2-YFP-I152L cell line for in vitro-based drug and toxicity testing in high-throughput screening format.

Add to Calendar ▼2017-07-10 00:00:002017-07-11 00:00:00Europe/LondonStem Cells for Drug Discovery and Toxicity Screening 2017Stem Cells for Drug Discovery and Toxicity Screening 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors